RNAi Developer Sirnaomics Targets Untapped Oncology Indications In China

The US- and China-based biotech is expanding three oncology-centered clinical studies of two TGF-1/COX-2-targeted siRNA drug candidates from the US into China.

china clinical trial — Sirnaomics brings China sites into international studies of lead siRNA assets • Source: Shutterstock

With no RNA interference-based therapy approved in China yet, Sirnaomics, Inc. is seeking to gain an edge over a growing number of local competitors by targeting cancer indications.

With dual headquarters in Gaithersburg, MD in the US and Suzhou in China, the Hong Kong-listed company is expanding oncology-centered...